Category - Markets

Canaccord Genuity upgraded STAAR Surgical (NASDAQ:STAA) to “buy” from “hold” and raised its price target to $15 from $11, suggesting a resolution to a FDA warning letter soon. The stock closed at $10.90 on Sept. 22...

William Blair upgraded Akari Therapeutics (NASDAQ:AKTX) to “outperform” from “market perform” after the company announced that, following its end-of-Phase-2 meeting with the FDA, it is advancing Coversin for the...

Profound Medical (TSXV:PRN; OTCQX:PRFMF) closed a bought deal financing for total proceeds of $10-million. The company sold 10 million units at a price of $1 each, with each unit consisting of one common share of...

Mackie Research downgraded Helius Medical Technologies (TSX:HSM) to “hold” from “speculative buy,” but maintained its price target of $2.70 (Canadian). The stock closed at $3.50 on Sept. 19.

Mackie Research Capital initiated coverage of Promis Neurosciences (TSX:PMN) with a “speculative buy” rating and price target of 50 cents, saying the company has a promising new path to target Alzheimer’s disease (AD)...

Leerink launched coverage of Synlogic (NASDAQ:SYBX) with an “outperform” rating and $25 price target. The stock closed at $18.73 on Sept. 18. Synlogic is a leader in the potentially revolutionary field of synthetic...

William Blair upgraded Arrowhead Pharmaceuticals (NASDAQ:ARWR) to “outperform” from “market perform” and raised its fair value estimate to $6 from $2 after the company’s R&D day on Sept. 14. The stock closed at $3...

BTIG downgraded Tactile Systems Technology (NASDAQ:TCMD) to “neutral” from “buy,” saying the stock is up more than 100% year-to-date, exceeding its price target of $35. The stock closed at $36.79 on Sept. 15. Tactile...

H.C. Wainwright slashed its price target for Applied Genetic Technologies (NASDAQ:AGTC) to $8 from $16 but maintained its “buy” rating after the company posted financing results below consensus for the fiscal year ended...

William Blair upgraded Sientra (NASDAQ:SIEN) to “outperform” from “market perform,” saying the company’s corporate strategy should begin to pay off over the next six-to-18 months. Sientra is a medical aesthetics company...